Comparing Astellas Pharma (OTCMKTS:ALPMY) and PainReform (NASDAQ:PRFX)

PainReform (NASDAQ:PRFX) and Astellas Pharma (OTCMKTS:ALPMY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for PainReform and Astellas Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1	0	0	0	1.00
Astellas Pharma	0	3	0	1	2.50

Earnings and Valuation

This table compares PainReform and Astellas Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20,000.00	38.23	-$5.02 million	($736.66)	-0.00
Astellas Pharma	$14.21 billion	1.83	$1.83 billion	$1.31	10.95

Astellas Pharma has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Astellas Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

PainReform has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.

Insider and Institutional Ownership

37.3% of PainReform shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares PainReform and Astellas Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Astellas Pharma	16.01%	25.79%	12.87%

Summary

Astellas Pharma beats PainReform on 9 of the 13 factors compared between the two stocks.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

About Astellas Pharma

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.